Xintela
0,458 SEK -4,18%1 investor følger denne virksomhed
Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.
Omsætning
80 t
EBIT %
-71.550 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
XINT
Daglig lav / høj pris
0,458 / 0,482
SEK
Markedsværdi
260,49 mio. SEK
Aktieomsætning
18,25 t SEK
Volumen
39 t
Seneste videoer
Finanskalender
Delårsrapport
22.11.2024
Årsrapport
28.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Flerie Invest AB | 55,5 % | 55,5 % |
Avanza Pension | 5,4 % | 5,4 % |
AB Svedala Finans | 1,5 % | 1,5 % |
Per Åke Oldentoft | 1,3 % | 1,3 % |
Evy Lundgren-Åkerlund | 1,2 % | 1,2 % |
Nordnet Pensionsförsäkring | 1,1 % | 1,1 % |
Derek Gregory Batcheller | 0,8 % | 0,8 % |
Jan Ivar Nordqvist | 0,8 % | 0,8 % |
Mats Hellström | 0,6 % | 0,6 % |
Inger Lundgren | 0,5 % | 0,5 % |
ViserAlle indholdstyper
Västra Hamnen Market Focus: Xintela: Activities below the surface
Xintela AB Interim Report January – June 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools